- Home
- BCE vs BIIB Comparison
BCE vs BIIB Comparison
Compare BCE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCE
- BIIB
- Stock Information
- Founded
- BCE 1880
- BIIB 1978
- Country
- BCE Canada
- BIIB United States
- Employees
- BCE N/A
- BIIB N/A
- Industry
- BCE
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- BCE
- BIIB Health Care
- Exchange
- BCE Nasdaq
- BIIB Nasdaq
- Market Cap
- BCE 29.4B
- BIIB 25.1B
- IPO Year
- BCE N/A
- BIIB 1991
- Fundamental
- Price
- BCE $26.78
- BIIB $157.90
- Analyst Decision
- BCE Hold
- BIIB Buy
- Analyst Count
- BCE 6
- BIIB 25
- Target Price
- BCE $42.25
- BIIB $260.48
- AVG Volume (30 Days)
- BCE 4.3M
- BIIB 1.8M
- Earning Date
- BCE 11-07-2024
- BIIB 10-30-2024
- Dividend Yield
- BCE 10.98%
- BIIB N/A
- EPS Growth
- BCE N/A
- BIIB 10.05
- EPS
- BCE 0.07
- BIIB 11.06
- Revenue
- BCE $18,105,777,409.00
- BIIB $9,607,500,000.00
- Revenue This Year
- BCE $0.36
- BIIB N/A
- Revenue Next Year
- BCE $0.80
- BIIB N/A
- P/E Ratio
- BCE $392.51
- BIIB $14.27
- Revenue Growth
- BCE N/A
- BIIB N/A
- 52 Week Low
- BCE $26.45
- BIIB $153.62
- 52 Week High
- BCE $41.77
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- BCE 19.17
- BIIB 24.44
- Support Level
- BCE $26.45
- BIIB $153.62
- Resistance Level
- BCE $27.50
- BIIB $175.86
- Average True Range (ATR)
- BCE 0.62
- BIIB 4.57
- MACD
- BCE -0.02
- BIIB -0.83
- Stochastic Oscillator
- BCE 10.48
- BIIB 16.73
About BCE BCE Inc.
BCE provides wireless, broadband, television, and landline phone services in Canada. It is one of the big three national wireless carriers, with over 10 million customers constituting about 30% of the market. It is also the ILEC (incumbent local exchange carrier—the legacy telephone provider) throughout much of the eastern half of Canada, including in the most populous Canadian provinces: Ontario and Quebec. Additionally, BCE has a media segment, which holds television, radio, and digital media assets. BCE licenses the Canadian rights to movie channels including HBO, Showtime, and Starz.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.